Brainstorm Cell Therapeutics Inc (BCLI) — Cash Flow Reinvestment Rate
Latest as of June 2018:
236.96x
Brainstorm Cell Therapeutics Inc (BCLI) has a Cash Flow Reinvestment Rate of 236.96x as of June 2018, reinvesting $13.03 Million (capex $215.00K plus investments $-12.82 Million) from operating cash flow of $55.00K. See Brainstorm Cell Therapeutics Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
236.96x
(Capex + Investments) / Operating CF
Total Reinvested
$13.03 Million
Capex + Investments
Operating Cash Flow
$55.00K
USD
Capital Expenditures
$215.00K
USD
Annual Cash Flow Reinvestment Rate for Brainstorm Cell Therapeutics Inc (None–None)
Year-by-year capital reinvestment analysis for Brainstorm Cell Therapeutics Inc. See Brainstorm Cell Therapeutics Inc (BCLI) flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow